OHE has authored numerous papers on personalised medicine with contributions to value frameworks, innovations in pricing and cost effectiveness analyses.
Four types of economic incentives for drugs and diagnostics are essential to encouraging more rapid progress in personalised medicine.
Adrian Towse, OHE’s Director, and Lou Garrison, a professor at the University of Washington, summarise the critical economic issues in the development of evidence of value for drugs and diagnostics that are part of personalised medicine.
Progress in personalised medicine is slower than some had expected, partly because of the science and partly because of insufficient economic incentives, particularly for investing in molecular diagnostics. In this open-access publication, OHE’s Adrian Towse and his co-authors examine nine case studies of diagnostics that have been successful in advancing personalised medicine.
Focusing on England, these two presentations describe the core economic considerations in making the most of targeted therapy.
OHE's Adrian Towse participated in a two-day workshop convened by the Biotherapy Development Association to discuss the process and problems that surround decisions about pricing and reimbursement for innovative oncology medicines in Europe.
OHE was involved in several sessions at the 9th World Congress of the International Heath Economics Association (iHEA). Prof Adrian Towse, OHE’s Director, and Prof Lou Garrison, OHE Visiting Senior Research Fellow for 2012-13 and a professor at the University of Washington, took part in a session focusing on barriers to utilisation and delivery of health service in developing countries.
The chapters in this book are based on contributions to a seminar organised jointly by the Office of Health Economics and the International Science Policy Foundation, and held at the Royal Society
The cost of R&D for a successful new medicine has been an important policy issue at least since the 1960s.
It is almost twenty years since I realised the significance of Schumpeter's work to the pharmaceutical industry.
The control of the major health problems of the early part of the twentieth century represents a triumph for medical progress in the past twenty-five years.
There has been a spectacular explosion of therapeutic progress over the past 35 years. The consequent improvements in public health may seem self-evident.
Professor Adrian Towse, OHE’s Director, joined Professor Sir John Bell and Professor Andrew Morris at the Science Media Centre last week to launch Realising the Potential of Stratified Medicine, a new report by the UK’s Academy of Medical Sciences. Adrian and Professor Lou Garrison, OHE Visiting Senior Research Fellow, were two of a dozen experts who oversaw the preparation of the report.
In this OHE lecture Professor Sackett sets out a compelling case for evidence-based medicine to be at the core of a comprehensive, tax-funded NHS that enjoys the confidence of the whole population.
This post reviews selected external OHE activities and publications from the past three months.
Each year, the OHE sponsors a lecture that explores a timely issue in medicine or health economics. At the 22nd Annual Lecture, held in June 2014, the issues and challenges of universal health care coverage in low- and middle-income countries were presented by Professor Anne Mills of the London School of Hygiene and Tropical Medicine.
A special issue of the Journal of Cancer Policy entitled ‘Value and Cancer’ includes three papers authored by OHE researchers.
Research and commentary by OHE team members appear regularly in external publications.
Join us on the evening of 9 June 2014 when OHE will welcome Professor Anne Mills of the London School of Hygiene and Tropical Medicine who will speak on Universal Health Care: the Holy Grail? Health services available to the whole population free of charge, and providing the best health advice and treatment, was the foundation stone for the creation of the National Health Service.
A new OHE Consulting Report considers the data capabilities in the UK for monitoring medicine use according to indication using real world data.
A new OHE Consulting Report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. The potential value of a new medicine is not likely to be fully known at the time of marketing approval. New uses can expand both the therapeutic and financial value of a particular medicine. In a new study, OHE Consulting seeks to describe and quantify such ‘value expansion’ for a cohort of cancer drugs.
OHE is pleased to announce the appointment of two new Senior Visiting Fellows: Professor David Parkin and Professor Lou Garrison.
How much it costs to research and develop a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter not just because of intellectual curiosity or for industry understanding of its performance, but because they are a key aspect of the international debate about the reasonableness of pharmaceutical prices and the magnitude of the long-term investments involved. The Office of Health Economics today released a comprehensive study of the cost of R&D for new medicines.
To celebrate its 50th Anniversary, OHE held a conference this week, The Challenges and Economics of Drug Development in 2022, which explored the likely evolution of the key aspects of drug development over the next ten years. The conference was attended by over 100 participants from the public and private sectors; speakers and panellists included leaders from drug regulatory agencies, health technology assessment (HTA) groups, payers, the pharmaceutical industry, private foundations, and academia.
OHE’s Yan Feng and Jorge Mestre-Ferrandiz have co-authored a new publication on quantifying the spillovers between public and private sector biomedical and health research and development funding in the UK.